15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN
Daniels, A.; McDade, E.; Llibre-Guerra, J. J.; Xiong, C.; Perrin, R. J.; Ibanez, L.; Supnet-Bell, C.; Cruchaga, C.; Goate, A. M.; Renton, A. E.; Benzinger, T. L. S.; Gordon, B. A.; Hassenstab, J.; Karch, C. M.; Popp, B.; Levey, A.; Morris, J.; Buckles, V.; Allegri, R.; Chrem, P.; Berman, S. B.; Chhatwal, J. P.; Farlow, M. R.; Fox, N. C.; Day, G. S.; Ikeuchi, T.; Jucker, M.; Lee, J.-H.; Levin, J.; Lopera, F.; Takada, L.; Sosa, A. L.; Martins, R.; Mori, H.; Noble, J. M.; Salloway, S.; Huey, E.; Rosa-Neto, P.; Sanchez-Valle, R.; Schofield, P. R.; Roh, J. H.; Bateman, R. J.; Dominantly Inherited A
Show abstract
This manuscript describes and summarizes the Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs), highlighting the wealth of longitudinal data, samples, and results from this human cohort study of brain aging and a rare monogenic form of Alzheimers disease (AD). DIAN Obs is an international collaborative longitudinal study initiated in 2008 with support from the National Institute on Aging (NIA), designed to obtain comprehensive and uniform data on brain biology and function in individuals at risk for autosomal dominant AD (ADAD). ADAD gene mutations in the amyloid protein precursor (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes are deterministic causes of ADAD, with virtually full penetrance, and a predictable age at symptomatic onset. Data and specimens collected are derived from full clinical assessments, including neurologic and physical examinations, extensive cognitive batteries, structural and functional neuro-imaging, amyloid and tau pathological measures using positron emission tomography (PET), flurordeoxyglucose (FDG) PET, cerebrospinal fluid and blood collection (plasma, serum, and whole blood), extensive genetic and multi-omic analyses, and brain donation upon death. This comprehensive evaluation of the human nervous system is performed longitudinally in both mutation carriers and family non-carriers, providing one of the deepest and broadest evaluations of the human brain across decades and through AD progression. These extensive data sets and samples are available for researchers to address scientific questions on the human brain, aging, and AD.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 94%
- Evaluation of a speech-based AI system for early detection of Alzheimer’s disease remotely via smartphones 94%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 94%
Similar papers in this journal
- Quantitative longitudinal predictions of Alzheimer's disease by multi-modal predictive learning 94%
- Frequency of Variants in Mendelian Alzheimer’s Disease Genes within the Alzheimer’s Disease Sequencing Project (ADSP) 94%
- Targeted Serum Metabolomic Profiling and Machine Learning Approach in Alzheimer’s Disease using the Alzheimer’s Disease Diagnostics Clinical Study (ADDIA) Cohort 93%
Similar papers in this journal
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 95%
- Real-world datasets for the International Registry for Alzheimer’s Disease and Other Dementias (InRAD) and other registries: an international consensus 94%
- Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research 94%